MicroRNAs in Skin Fibrosis

Andrew Mamalis, Jared Jagdeo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The pathogenesis and maintenance of skin fibrosis is a result of complex interactions between a number of cellular pathways, cell types, and extracellular matrix molecules. miRNAs regulate these pathways and contribute to skin fibrosis through TGF-β signaling, ECM deposition, fibroblast proliferation and differentiation, and epithelial-mesenchymal transition (EMT). Some miRNAs up-regulate these processes and are known as profibrotic; others, known as antifibrotic, inhibit them, leading to skin fibrosis. miRNA therapies are aimed at either increasing the levels of antifibrotic miRNAs or decreasing those of profibrotic miRNAs. There are few effective treatments for fibrotic skin diseases, and we believe that future miRNA therapies might alter the management paradigm of skin fibrosis and improve patient outcomes and quality of life.

Original languageEnglish (US)
Title of host publicationMicroRNA in Regenerative Medicine
PublisherElsevier Inc.
Pages311-328
Number of pages18
ISBN (Print)9780124058583, 9780124055445
DOIs
StatePublished - Dec 23 2014

Fingerprint

MicroRNAs
Fibrosis
Skin
Epithelial-Mesenchymal Transition
Skin Diseases
Extracellular Matrix
Up-Regulation
Therapeutics
Fibroblasts
Maintenance
Quality of Life

Keywords

  • Collagen
  • Epithelial-mesenchymal transition
  • Extracellular matrix
  • Fibroblast
  • MicroRNA
  • MiRNA
  • Platelet-derived growth factor
  • Scleroderma
  • Skin fibrosis
  • Therapeutics
  • Transforming growth factor

ASJC Scopus subject areas

  • Immunology and Microbiology(all)

Cite this

Mamalis, A., & Jagdeo, J. (2014). MicroRNAs in Skin Fibrosis. In MicroRNA in Regenerative Medicine (pp. 311-328). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-405544-5.00012-5

MicroRNAs in Skin Fibrosis. / Mamalis, Andrew; Jagdeo, Jared.

MicroRNA in Regenerative Medicine. Elsevier Inc., 2014. p. 311-328.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mamalis, A & Jagdeo, J 2014, MicroRNAs in Skin Fibrosis. in MicroRNA in Regenerative Medicine. Elsevier Inc., pp. 311-328. https://doi.org/10.1016/B978-0-12-405544-5.00012-5
Mamalis A, Jagdeo J. MicroRNAs in Skin Fibrosis. In MicroRNA in Regenerative Medicine. Elsevier Inc. 2014. p. 311-328 https://doi.org/10.1016/B978-0-12-405544-5.00012-5
Mamalis, Andrew ; Jagdeo, Jared. / MicroRNAs in Skin Fibrosis. MicroRNA in Regenerative Medicine. Elsevier Inc., 2014. pp. 311-328
@inbook{2c8c8b24f3f8423eb140f41663767270,
title = "MicroRNAs in Skin Fibrosis",
abstract = "The pathogenesis and maintenance of skin fibrosis is a result of complex interactions between a number of cellular pathways, cell types, and extracellular matrix molecules. miRNAs regulate these pathways and contribute to skin fibrosis through TGF-β signaling, ECM deposition, fibroblast proliferation and differentiation, and epithelial-mesenchymal transition (EMT). Some miRNAs up-regulate these processes and are known as profibrotic; others, known as antifibrotic, inhibit them, leading to skin fibrosis. miRNA therapies are aimed at either increasing the levels of antifibrotic miRNAs or decreasing those of profibrotic miRNAs. There are few effective treatments for fibrotic skin diseases, and we believe that future miRNA therapies might alter the management paradigm of skin fibrosis and improve patient outcomes and quality of life.",
keywords = "Collagen, Epithelial-mesenchymal transition, Extracellular matrix, Fibroblast, MicroRNA, MiRNA, Platelet-derived growth factor, Scleroderma, Skin fibrosis, Therapeutics, Transforming growth factor",
author = "Andrew Mamalis and Jared Jagdeo",
year = "2014",
month = "12",
day = "23",
doi = "10.1016/B978-0-12-405544-5.00012-5",
language = "English (US)",
isbn = "9780124058583",
pages = "311--328",
booktitle = "MicroRNA in Regenerative Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - MicroRNAs in Skin Fibrosis

AU - Mamalis, Andrew

AU - Jagdeo, Jared

PY - 2014/12/23

Y1 - 2014/12/23

N2 - The pathogenesis and maintenance of skin fibrosis is a result of complex interactions between a number of cellular pathways, cell types, and extracellular matrix molecules. miRNAs regulate these pathways and contribute to skin fibrosis through TGF-β signaling, ECM deposition, fibroblast proliferation and differentiation, and epithelial-mesenchymal transition (EMT). Some miRNAs up-regulate these processes and are known as profibrotic; others, known as antifibrotic, inhibit them, leading to skin fibrosis. miRNA therapies are aimed at either increasing the levels of antifibrotic miRNAs or decreasing those of profibrotic miRNAs. There are few effective treatments for fibrotic skin diseases, and we believe that future miRNA therapies might alter the management paradigm of skin fibrosis and improve patient outcomes and quality of life.

AB - The pathogenesis and maintenance of skin fibrosis is a result of complex interactions between a number of cellular pathways, cell types, and extracellular matrix molecules. miRNAs regulate these pathways and contribute to skin fibrosis through TGF-β signaling, ECM deposition, fibroblast proliferation and differentiation, and epithelial-mesenchymal transition (EMT). Some miRNAs up-regulate these processes and are known as profibrotic; others, known as antifibrotic, inhibit them, leading to skin fibrosis. miRNA therapies are aimed at either increasing the levels of antifibrotic miRNAs or decreasing those of profibrotic miRNAs. There are few effective treatments for fibrotic skin diseases, and we believe that future miRNA therapies might alter the management paradigm of skin fibrosis and improve patient outcomes and quality of life.

KW - Collagen

KW - Epithelial-mesenchymal transition

KW - Extracellular matrix

KW - Fibroblast

KW - MicroRNA

KW - MiRNA

KW - Platelet-derived growth factor

KW - Scleroderma

KW - Skin fibrosis

KW - Therapeutics

KW - Transforming growth factor

UR - http://www.scopus.com/inward/record.url?scp=84943223979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943223979&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-405544-5.00012-5

DO - 10.1016/B978-0-12-405544-5.00012-5

M3 - Chapter

AN - SCOPUS:84943223979

SN - 9780124058583

SN - 9780124055445

SP - 311

EP - 328

BT - MicroRNA in Regenerative Medicine

PB - Elsevier Inc.

ER -